News >

ASCO Issues New Guideline for Neoadjuvant Chemotherapy in Ovarian Cancer

Allie Strickler @Alliejayes
Published: Monday, Aug 08, 2016

Alexi A. Wright, MD

Alexi A. Wright, MD

Neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women with newly diagnosed, advanced ovarian cancer, according to a new joint clinical practice guideline from ASCO and the Society of Gynecologic Oncology (SGO).

While the standard of care in this setting is primary cytoreductive surgery (PCS) followed by chemotherapy, the new guideline, which was published today in the Journal of Clinical Oncology suggests that some patients may benefit more from NACT and interval cytoreduction.

“This guideline is a big step forward in one of the most contentious areas within gynecologic oncology,” said Alexi A. Wright, MD, co-chair and ASCO’s representative on the Expert Panel that worked on developing the guideline.

The evidence supporting these recommendations comes from four phase III clinical trials, which found that for women with stage IIIC or IV epithelial ovarian cancer, NACT and interval cytoreduction were preferable to adjuvant chemotherapy and primary cytoreduction with respect to overall and progression-free survival.

However, it is important to note that women with suspected stage IIIC or IV invasive epithelial ovarian cancer should seek evaluation by a gynecologic oncologist before beginning either type of therapy, according to one of the new guideline recommendations. Such an evaluation should include a CT of the abdomen and pelvis with oral and intravenous contrast and chest imaging (CT preferred) to determine the extent of disease, as well as whether the patient is a candidate to undergo PCS with acceptable risks and associated morbidity.

Other tools may be used to assess patients as well, such as laparoscopic evaluation or additional radiographic imaging (FDG-PET scan or diffusion-weighted MRI). However, the use of these methods has been found to be inferior to CT findings at this time.

For women who are assessed by a gynecologic oncologist and are determined to be a fit for PCS, with potentially resectable disease, either PCS or NACT can be offered as treatment. With respect to progression-free and overall survival, as well as perioperative morbidity and mortality, NACT has been found to be generally noninferior to PCS. Neoadjuvant chemotherapy is associated with less peri- and postoperative morbidity and mortality and shorter hospitalizations. Primary cytoreductive surgery, on the other hand, may offer superior survival results in patients with newly diagnosed stage IIIC or IV epithelial ovarian cancer.

The benefits of these respective therapies come from the results of 4 randomized clinical trials comparing NACT and interval cytoreduction with primary cytoreduction and chemotherapy among women with advanced ovarian cancer.

In the EORTC 55971 trial, NACT was generally found to be noninferior to PCS in terms of overall survival, though perioperative morbidity and mortality were lower in the neoadjuvant arm. Analyses of subgroups found that patients with stage IIIC cancer and less extensive metastatic tumors had higher survival when treated with PCS rather than NACT, while patients with stage IV disease and larger metastatic tumors had better survival with NACT.

The CHORUS trial also found NACT to be noninferior to PCS with respect to overall survival. However, postoperative mortality and serious (grade 3 or 4) postoperative adverse events were less common in patients enrolled in the NACT arm than in the PCS arm.

Similar results were found in the JCOG0602 trial, where patients in the neoadjuvant arm experienced less blood loss and ascites during or after surgery and were less likely to experience grade 3 or 4 nonhematologic adverse events after surgery.

Critics of the EORTC and CHORUS trials (which are, to date, the only published randomized phase III trials comparing NACT and PCS) have noted that both studies had a shorter median overall survival than what has been reported in previous findings. However, these short survival results may actually reflect trial participants rather than differences in treatment. The population of patients was older (≥65 years old), had poorer performance status, and had higher stage tumors compared with other trials. Therefore, it remains to be seen whether these results apply to younger populations with better performance status and/or less bulky disease.

Though many of these findings seem to favor neoadjuvant chemotherapy, it is not the ideal choice of therapy for every woman with advanced ovarian cancer. According to the new guideline, patients with a high likelihood of achieving cytoreduction to <1 cm (ideally to no visible disease) with acceptable morbidity are recommended to receive primary cytoreductive surgery. However, for women with a high preoperative risk profile or a low likelihood of achieving cytoreduction to <1 cm of residual disease (ideally to no visible disease), NACT is preferred instead.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication